Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Comell University has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. Prosecution involves 1 distinct examiner and 1 distinct art unit. The presence of 1 distinct art unit suggests that the university's biotechnological or pharmaceutical innovation is being evaluated by a single specialized group. This focused review process applies to the 1 pending office action currently active for the institution.
Rachel E. Martin is the busiest examiner, responsible for the 1 pending office action. This action constitutes the 1 pending office action currently active. Since Rachel E. Martin is the only one of the 1 distinct examiners involved, this individual has sole oversight of the current pending matter. The 1 busiest examiner pending action assigned to this examiner represents the total active workload for the university.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MARTIN, RACHEL E | 1 | 53.6% | +56.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18575597 | ENHANCED EXPRESSION OF AN AROMATIC AMINO ACID DECARBOXYLASE (AADC) IN THE SUBSTANTIA NIGRA FOR THE TREATMENT OF PARKINSON'S DISEASE | MARTIN, RACHEL E | 28d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18575597 | ENHANCED EXPRESSION OF AN AROMATIC AMINO ACID DECARBOXYLASE (AADC) IN THE SUBSTANTIA NIGRA FOR THE TREATMENT OF PARKINSON'S DISEASE | MARTIN, RACHEL E | 28d overdue |
| Art Unit | Apps |
|---|---|
| 1657 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18575597 | ENHANCED EXPRESSION OF AN AROMATIC AMINO ACID DECARBOXYLASE (AADC) IN THE SUBSTANTIA NIGRA FOR THE TREATMENT OF PARKINSON'S DISEASE | MARTIN, RACHEL E | 1657 | §102§103§112 | Non-Final OA | 28d overdue | Pending | Dec 29, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial